OcyonBio Announces Biosimilar Solutions To Begin GMP Manufacturing In Puerto Rico

Publication Date28 March 2022
SubjectFood, Drugs, Healthcare, Life Sciences, Biotechnology & Nanotechnology
Law FirmGoodwin Procter LLP
AuthorMs Gabriella Montes

Last week, OcyonBio announced a manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc. in Puerto Rico.

According to the press release "OcyonBio is creating an advanced therapy contract development, manufacturing organization (CDMO) that provides pre-clinical through commercial manufacturing, including process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities." Robert Salcedo, the CEO of OcyonBio, stated, "[w]ith our partnership development manufacturing organization model, OcyonBio is the perfect partner to usher in these biosimilars to the U.S. Biosimilar Solutions, Inc...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT